EER

/Kevin Orwig/

*Examiner

INFORMATION DISCLOSURE CITATION		APPLN. NO.		ATTY. DKT. NO.			
		10/594,436		1050-4			
E		APPLIC	•	1000 1			
E 40 ES							
1 2 5001 (AR	several sheets if necessary)		HITAKE et al.	GROUP			
1 1 200 18							
<u> </u>		Septe		Not Known			
TRADEMART			U.S. PATENT DOCUMENTS				
*EXAMINER						FILING	DATE
INITIAL	DOCUMENT NUMBER	DATE	NAME_	CLASS	SUBCLASS	IF APPRO	OPRIATE
	AR 5,035,899	07/1991	Saeki et al.				
	BR				-		
	CR						
	DR DR	·					
	ER						
	FR						
	GR		<u> </u>				
		FC	DREIGN PATENT DOCUMENTS				
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO
ŀ	HR 0670718 B1	09/1995	Europe				
	IR						
	JR						
	KR						
	LR						<u> </u>
	OTHER DOC	UMENTS ((including Author, Title, Pertinent	nages Date	etc)		L
M			le sodium) delayed-release tablets,				
	FDA/Center for Drug Evaluation and Research's Orange Book listings for ACIPHEX (rabeprazole sodium)						
			998, www.accessdata.fda.gov/script				
0		n translatio	translation of "PARIET tablet" package inserts and certificates, 22 pages (1998 and				
	2001).						
	R Eisai Co. Ltd., "Eisai r	eceives Eu	uropean marketing authorization for	PARIET (rabe	prazole sod	ium) for	
	Zollinger-Eillson synd	rome Japa	an Corporate News (JCN) Network,	one page (07	/2004).		
٦	News (JCN) Network,	one nade	ation seeking additional indication for	r PARIET IN J	apan Japar	Corpor	ate
T R			Ltd., "Teva annouces approval of ra	henrazole sod	lium delaver	d-releas	
'	tablets" PipelineRevie	w.com. on	ne page (02/2007).	beprazoie 300	idili delayet	2-1 CICa3	C
S		, ,	, , , , , , , , , , , , , , , , , , ,				
Т	R						
Ū	R						
V	R						
	/R					-	
X							· ·
	R	·					
	R						
	AR .						
	BR SP						
	CR				<u> </u>		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

03/12/2009